Keywords: etanercept; long-term safety; open-label; pediatric population; plaque psoriasis; AE; adverse event; CDC; Centers for Disease Control and Prevention; FDA; Food and Drug Administration; HRQOL; health-related quality of life; JIA; juvenile idiopathic arthri
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ADPKD; autosomal dominant polycystic kidney disease; ALADIN; Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study; CRISP; Consortium for Radiologic Imaging Studies in Polycystic Kidney Disease; CT; computed tomography; eGFR; estimated
Evaluation of perampanel as monotherapy for focal seizures: Experience from open-label extension studies
Keywords: AMPA; α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; bid; twice daily; FDA; Food and Drug Administration; OLEx; open-label extension; qam; every morning; qd; once daily; qhs; every night at bedtime; qpm; every evening; SG; secondarily generalized;
Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents
Keywords: C1-esterase; Hereditary angioedema; Adolescent; Safety; Efficacy; Ruconest; Pharmacokinetics; AE; Adverse event; C1-INH; C1-esterase inhibitor; Cmax; Maximum concentration; HAE; Hereditary angioedema; IV; Intravenous; OLE; Open-label extension; RCT; Rando
Recombinant Human-C1 Inhibitor Is Effective and Safe for Repeat Hereditary Angioedema Attacks
Keywords: Hereditary angioedema; Recombinant human C1 esterase inhibitor; Repeat attacks; C1INH; C1 Esterase inhibitor; HAE; Hereditary angioedema; HRI; Host-related impurities; IS; Investigator Score; OLE; Open-label extension; rhC1INH; Recombinant human C1 estera
Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies
Keywords: AED; antiepileptic drug; DB; double blind; MedDRA; Medical Dictionary for Regulatory Activities; MTD; maximum tolerated dose; OLE; open-label extension; PBO; placebo; PER; perampanel; TEAE; treatment-emergent adverse event; Antiepileptic drugs; Epilepsy;
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis
Keywords: interleukin 17; ixekizumab; long-term; monoclonal antibodies; open label; psoriasis; 1 year; AE; adverse event; NRI; nonresponder imputation; OLE; open-label extension; PASI; Psoriasis Area and Severity Index; PASI75; 75% improvement from baseline on the
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
Keywords: adalimumab; anti-tumor necrosis factor therapy; clinical trial; efficacy; long-term treatment; open-label; psoriasis; safety; AE; adverse events; eow; every other week; LOCF; last observation carried forward; OLE; open-label extension; PASI; Psoriasis A
Reporting and analysis of open-label extension studies of anti-epileptic drugs
Keywords: Open-label extension; Anti-epileptic drugs; Efficacy; ITT analysis